• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

    5/13/24 7:44:39 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email

    Investors can contact the law firm at no cost to learn more about recovering their losses

    ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities.

    Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

    On April 1, 2024, Ocugen filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission. The report disclosed that Ocugen discovered accounting errors while preparing its financial statements for the year ended December 31, 2023. These errors were related to the application of U.S. GAAP in certain agreements under a collaboration with a business partner. Due to these findings, Ocugen announced that its audited consolidated financial statements for each fiscal year starting January 1, 2020, and its unaudited interim condensed consolidated financial statements for the first three quarters of those years should no longer be relied upon and will be restated. This also applies to associated earnings releases and any communications describing these financial statements. Additionally, Ocugen acknowledged a material weakness in its internal control over financial reporting that persisted during these periods and admitted that its internal controls and disclosure procedures were ineffective as of December 31, 2023.

    Following this announcement, Ocugen's stock price dropped by $0.16 per share, or 10.38%, closing at $1.38 per share on April 2, 2024.

    Please visit our website to review more information and submit your transaction information.

    The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

    Lesley F. Portnoy, Esq.

    Admitted CA and NY Bar

    [email protected]

    310-692-8883

    www.portnoylaw.com

    Attorney Advertising



    Primary Logo

    Get the next $OCGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    More analyst ratings

    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 3 filed by new insider Chandrasekhar Satishchandran

      3/A - Ocugen, Inc. (0001372299) (Issuer)

      6/12/25 4:28:45 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chandrasekhar Satishchandran

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:37 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Coleman Blaise

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:31 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    SEC Filings

    See more
    • SEC Form 144 filed by Ocugen Inc.

      144 - Ocugen, Inc. (0001372299) (Subject)

      6/11/25 5:46:07 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      6/5/25 4:37:15 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      5/9/25 9:45:30 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

      MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-r

      6/16/25 7:02:34 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen To Present at BIO International Convention 2025

      MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company's novel modifier gene therapy platform targeting major blindness diseases with a one-time therapy for life. "We are excited to return to BIO this year on the heels of our recent execution of a bindin

      6/11/25 7:30:50 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

      Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pig

      6/5/25 7:02:16 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/12/24 4:59:47 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/4/24 1:43:41 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      10/16/24 12:41:30 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ocugen with a new price target

      Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

      10/15/24 8:07:55 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50

      3/1/23 9:04:17 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Ocugen with a new price target

      Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00

      8/23/22 7:19:06 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care